Trial Profile
Irbesartan/Hydrochlorothiazide to Control Elevated Blood Pressure to Target in Moderate to Severe Hypertensive Patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Apr 2013
Price :
$35
*
At a glance
- Drugs Irbesartan/hydrochlorothiazide (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Sanofi
- 18 Apr 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Apr 2009 Planned number of patients changed from 500 to 503 as reported by ClinicalTrials.gov.
- 20 May 2008 New trial record.